Gastrointestinal Adverse Events in Rheumatic Disease Patients Treated With TNF-α Inhibitors Versus IL-17 Inhibitors: Evidence from a Propensity-Matched Retrospective Study (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2781; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Cohort 1 (n=12,873) received IL-17 inhibitors secukinumab, ixekizumab or brodalumab. Cohort 2 (n=12,873) received TNF-α inhibitors etanercept, adalimumab, infliximab, golimumab, or certolizumab pegol... IL-17 inhibitors are associated with lower risks of several GI adverse events compared to TNF-α inhibitors, particularly for colitis, pancreatitis, esophagitis, and gastritis. Slightly elevated hepatitis risk warrants further investigation. These findings inform therapeutic decision-making in rheumatic disease management."
Adverse events • Retrospective data • Ankylosing Spondylitis • Axial Spondyloarthritis • Gastroenterology • Gastrointestinal Disorder • Hepatology • Inflammatory Arthritis • Pancreatitis • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A
|